On his podcast, Andrew Huberman, MD, professor of neurobiology and ophthalmology at Stanford Universitys school of medicine, shared a potential, and slightly gory, origin story for BPC-157
*Based on SURMOUNT-1 (NCT04184622), a phase 3, randomized, double-blind, placebo-controlled trial in adults with obesity (BMI 30) or overweight (BMI 27) with 1 weight-related comorbidity, excluding T2D
There are also clinical trials in progress for the potential use of setmelanotide in the treatment of acquired hypothalamic obesity, which can be seen as hypothalamic substitution therapy (e.g., following tumor treatment in hypothalamic region) [38,39,40,41]
This potent injection is formulated to enhance your bodys natural fat-burning processes, increase energy levels, and improve metabolism
There are no natural substitutes for GLP-1 RA medications
Persistent dry mouth can lead to long-term dental issues and discomfort